Date Time
Penn Study Suggests Those Who Had COVID-19 May Only Need One Vaccine Dose
PHILADELPHIA People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published today in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response. The team found that those who did not have COVID-19 called COVID naïve did not have a full immune response until after receiving their second vaccine dose, reinforcing the importance of completing the two recommended doses for achieving strong levels of immunity.
Black neighborhoods have higher maternal morbidity rates
whyy.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from whyy.org Daily Mail and Mail on Sunday newspapers.
citybizlist : Washington DC : David Nevins Interviews Dr Samuel Hahn, Founder of Maryland Center for Facial Plastic Surgery
citybizlist.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citybizlist.com Daily Mail and Mail on Sunday newspapers.
E-Mail
PHILADELPHIA A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania found significant disparities in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs proven to treat type 2 diabetes, with usage remaining low with Black, Asian, and lower-income groups despite an increase in overall usage for patients with type 2 diabetes. The study is published in
JAMA Network Open. Study after study, including large randomized trials, have demonstrated a cardio-protective and kidney-protective effect of this class of medications said the study s lead author, Lauren Eberly, MD, MPH, a cardiology fellow at the University of Pennsylvania. We know there are already higher rates of heart failure and kidney disease among Black patients. What is concerning is that this is a therapy we know prevents death from those conditions and prevents progression from those conditions, and yet, we found that Black patients are less